SB203580是一种p38 MAPK抑制剂，在THP-1细胞中IC₅₀为0.3-0.5μM，对SAPK3(106T)和SAPK4(106T)选择性低10倍，且阻断PKB磷酸化，IC₅₀为3-5μM。SB203580是第一个被报道的p38抑制剂。

＞98%

Store at -20℃ for one year（Powder）；Store at 2-4℃ for two weeks；Store at -20℃ for six months after dissolution.

Adezmapimod；RWJ 64809

white to off-white powder

DMSO：43 mg/mL (113.92 mM)

p38 MAPK；PKB

SB203580 inhibits the IL-2-induced proliferation of primary human T cells, murine CT6 T cells, or BAF F7 B cells with an IC₅₀ of 3–5 μm. SB203580 also inhibits IL-2-induced p70S6 kinase activation, although the concentration required is slightly higher with an IC₅₀ above 10 μm. SB203580 also inhibits the activity of PDK1 in a dose-dependent manner with an IC₅₀ in the 3–10 μm range. SB203580 inhibits p38-MAPK stimulation of MAPKAPK2 with an IC₅₀ of approximately 0.07 μM, whereas inhibits total SAPK/JNK activity with an IC₅₀ of 3–10 μM. SB203580 at higher concentrations activates the ERK pathway, which subsequently enhances NF-κB transcriptional activity. SB203580 induces autophagy in human hepatocellular carcinoma (HCC) cells.

SB203580 protects pig myocardium against ischemic injury in an in vivo model. SB203580 is effective to prevent and treat the disease in MRL/lpr mice model of Systemic lupus erythematosus (SLE).